• Mohamad A Sabbah, Christa Schorr, Quinn A Czosnowski, Krystal Hunter, Marc C Torjman, Henry S Fraimow, Sergio Zanotti, and Constantine Tsigrelis.
• From the 1 Division of Infectious Diseases.
• Infect Dis (Lond). 2015 Apr 1; 47 (4): 197-202.

BackgroundAntimicrobial agents used to treat Clostridium difficile infection (CDI), such as metronidazole and vancomycin, have been used during antibiotic treatment of other infections to try to prevent the development of CDI. We evaluated the hypothesis that intensive care unit (ICU) patients who receive metronidazole as part of an antibiotic treatment regimen for sepsis have a lower risk of subsequently developing CDI.MethodsThis was a nested case-control study in a cohort of ICU patients who received antibiotic therapy for sepsis.ResultsA total of 10 012 patients aged ≥ 18 years were admitted to the Cooper University Hospital medical/surgical ICU from 1/1/2003 to 12/31/2008. After applying inclusion criteria including having received antibiotic therapy for sepsis and subsequently having developed CDI, 67 cases were identified. The cases were matched for age, gender, date of ICU admission, and hospital length of stay to 67 controls that also received antibiotic therapy for sepsis but did not subsequently develop CDI. In the multivariate analysis, there was no association between metronidazole exposure and the risk of CDI (odds ratio (OR) = 0.57; p = 0.23). The only significant associations on multivariate analysis were antifungal therapy (OR = 0.30; p = 0.02) and aminoglycoside and/or colistin therapy (OR = 0.17; p = 0.02).ConclusionsNo association was found between metronidazole use and subsequent CDI in ICU patients who received antibiotic therapy for sepsis.

27 keywords...

hide…